截至9月30日，君实生物股东户数3.59万，较上期增加15.17%；人均流通股21361股，较上期减少 12.96%。2025年1月-9月，君实生物实现营业收入18.06亿元，同比增长42.06%；归母净利润-5.96亿元， 同比增长35.72%。 机构持仓方面，截止2025年9月30日，君实生物十大流通股东中，易方达上证科创板50ETF（588080） 位居第七大流通股东，持股1939.29万股，相比上期减少282.03万股。华夏上证科创板50成份ETF （588000）位居第八大流通股东，持股1897.20万股，相比上期减少1074.47万股。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融资方面，君实生物当日融资买入5342.70万元。当前融资余额14.64亿元，占流通市值的5.32%，融资 余额超过近一年90%分位水平，处于高位。 融券方面，君实生物1月30日融券偿还2350.00股，融券卖出300.00股，按当日收盘价计 ...

Core Viewpoint - Junshi Biosciences has experienced fluctuations in stock price and trading volume, with a recent decline in share price despite a year-to-date increase. The company is involved in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins, with a significant portion of its revenue coming from drug sales [1][2]. Group 1: Stock Performance - On January 16, Junshi Biosciences' stock fell by 2.00%, trading at 36.72 CNY per share, with a total market capitalization of 37.7 billion CNY [1]. - The stock has increased by 7.49% year-to-date but has seen a decline of 6.33% over the last five trading days [1]. - The trading volume was 1.76 billion CNY, with a turnover rate of 0.62% [1]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06% [2]. - The company recorded a net profit attributable to shareholders of -596 million CNY, which is a 35.72% increase compared to the previous period [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased to 35,900, a rise of 15.17% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 12.96% to 21,361 shares [2]. Group 4: Company Overview - Junshi Biosciences, established on December 27, 2012, and listed on July 15, 2020, is based in Shanghai and focuses on the development and commercialization of monoclonal antibody drugs and other therapeutic proteins [1]. - The company's main revenue sources include drug sales (90.67%), technology licensing and royalties (8.74%), and technical services (0.59%) [1].

Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price and significant trading activity, indicating potential investor concerns and market volatility [1] - On January 14, Junshi Biosciences' stock fell by 2.36%, with a trading volume of 678 million yuan, and a net financing outflow of 24.32 million yuan [1] - As of January 14, the total margin balance for Junshi Biosciences was 1.341 billion yuan, with a financing balance of 1.325 billion yuan, representing 4.50% of the circulating market value, which is above the 60th percentile of the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% increase [2] - As of September 30, 2025, the number of shareholders increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]

Core Viewpoint - Junshi Biosciences' stock price has shown fluctuations, with a recent decline of 2.11%, while the company has experienced a year-to-date increase of 12.76% in stock value [1][2]. Group 1: Stock Performance - As of January 14, Junshi Biosciences' stock price is reported at 38.52 CNY per share, with a trading volume of 4.05 billion CNY and a market capitalization of 39.548 billion CNY [1]. - The stock has increased by 12.76% year-to-date, with a 1.90% rise over the last five trading days and a 5.30% increase over the last 20 days, while it has slightly decreased by 0.39% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences achieved a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was -596 million CNY, reflecting a year-on-year increase of 35.72% in losses [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Biosciences is 35,900, which is an increase of 15.17% compared to the previous period. The average number of circulating shares per shareholder is 21,361, a decrease of 12.96% [2]. - Among the top ten circulating shareholders, E Fund's SSE STAR 50 ETF holds 19.3929 million shares, a decrease of 2.8203 million shares from the previous period, while Huaxia's SSE STAR 50 ETF holds 18.9720 million shares, down by 1.0745 million shares [3].

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Junshi Biosciences, indicating a significant level of financing activity and a high balance in margin trading [1][2] - On January 13, Junshi Biosciences saw a stock price increase of 1.71% with a trading volume of 635 million yuan, and the net financing purchase was 4.0162 million yuan [1] - As of January 13, the total margin trading balance for Junshi Biosciences reached 1.365 billion yuan, with a financing balance of 1.349 billion yuan, accounting for 4.47% of the circulating market value [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, reflecting a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a 35.72% increase year-on-year [2] - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2]

Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a decline in stock price while showing significant activity in financing and margin trading, indicating a high level of investor interest and potential volatility in the stock [1][2] Group 2 - On January 12, Junshi Biosciences' stock fell by 1.30%, with a trading volume of 5.09 billion yuan. The financing buy-in amount for the day was 60.41 million yuan, while the financing repayment was 44.22 million yuan, resulting in a net financing buy of 16.19 million yuan [1] - As of January 12, the total margin trading balance for Junshi Biosciences was 1.36 billion yuan, with the financing balance accounting for 4.54% of the circulating market value, which is above the 70th percentile level over the past year [1] - In terms of securities lending, on January 12, Junshi Biosciences had 6171 shares repaid and 800 shares sold short, with a short selling amount of 31,000 yuan. The remaining short selling volume was 388,300 shares, with a short selling balance of 15.02 million yuan, exceeding the 90th percentile level over the past year [1] Group 3 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, a year-on-year increase of 35.72% [2] - As of September 30, 2025, the top ten circulating shareholders included E Fund's SSE STAR 50 ETF and Huaxia's SSE STAR 50 Component ETF, with both funds reducing their holdings compared to the previous period [2]

Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown significant trading activity, with a notable increase in stock price and substantial financing and margin trading data indicating a high level of investor interest [1][2] Group 2 - On January 9, Junshi Biosciences' stock price increased by 4.09%, with a trading volume of 520 million yuan [1] - The financing buy-in amount for Junshi Biosciences on the same day was 47.67 million yuan, while the financing repayment was 55.29 million yuan, resulting in a net financing outflow of 7.62 million yuan [1] - As of January 9, the total financing and margin trading balance for Junshi Biosciences was 1.344 billion yuan, with the financing balance accounting for 4.42% of the circulating market value, indicating a high level compared to the past year [1] - In terms of margin trading, on January 9, Junshi Biosciences had a margin repayment of 5,125 shares and a margin sell-out of 3,000 shares, with the sell-out amount calculated at 117,600 yuan [1] - The margin balance was 15.43 million yuan, exceeding the 90th percentile level over the past year, indicating a high level of short selling activity [1] Group 3 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year increase of 35.72% [2] - Among the top ten circulating shareholders, E Fund's Science and Technology Innovation Board 50 ETF held 19.39 million shares, a decrease of 2.82 million shares from the previous period [2] - Another major shareholder, Huaxia's Science and Technology Innovation Board 50 Component ETF, held 18.97 million shares, down by 1.07 million shares from the previous period [2]

Group 1 - The core viewpoint of the news is that Junshi Biosciences has seen a significant stock price increase, with a 10.71% rise over the past three days, closing at 37.82 CNY per share [1] - Junshi Biosciences is primarily engaged in the research and commercialization of monoclonal antibody drugs, with 90.67% of its revenue coming from drug sales [1] - The company was founded on December 27, 2012, and went public on July 15, 2020, with a current market capitalization of 38.829 billion CNY [1] Group 2 - Tianzhi Fund has a significant holding in Junshi Biosciences, with its Tianzhi New Consumption Mixed Fund (350008) holding 18,100 shares, representing 4.75% of the fund's net value [2] - The Tianzhi New Consumption Mixed Fund has generated a floating profit of approximately 66,200 CNY during the three-day stock price increase [2] - The fund was established on August 4, 2011, and has a current scale of 15.7711 million CNY, with a year-to-date return of 5.18% [2]

Group 1 - The core viewpoint of the news is that Junshi Biosciences experienced a significant increase in stock price and trading volume on January 5, with a rise of 6.62% and a transaction amount of 518 million yuan [1] - On January 5, Junshi Biosciences had a financing buy-in amount of 36.69 million yuan and a financing repayment of 52.40 million yuan, resulting in a net financing buy of -15.71 million yuan [1] - As of January 5, the total balance of margin trading for Junshi Biosciences was 1.341 billion yuan, with a financing balance of 1.327 billion yuan, accounting for 4.75% of the circulating market value, which is above the 60th percentile level over the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - For the period from January to September 2025, Junshi Biosciences achieved an operating income of 1.806 billion yuan, representing a year-on-year growth of 42.06%, while the net profit attributable to shareholders was -596 million yuan, an increase of 35.72% year-on-year [2] - As of September 30, 2025, the number of shareholders of Junshi Biosciences was 35,900, an increase of 15.17% compared to the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [2]

Core Viewpoint - The announcement from Junshi Bioscience indicates that shareholder Tan Ying Investment plans to reduce its stake by up to 20.53 million shares, representing 2% of the total share capital, through block trading between January 13, 2026, and April 10, 2026, due to fund duration and liquidity arrangements [1]. Group 1: Shareholder Actions - Tan Ying Investment currently holds 59.45 million shares, accounting for 5.79% of the total share capital [1]. - The initial holding of Tan Ying Investment was 71.45 million shares, which represented 6.96% of the total share capital [2]. - Since June 20, 2025, Tan Ying Investment has cumulatively reduced its holdings by 12 million shares, realizing approximately 526 million yuan [2]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Bioscience reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year growth of 35.72% [3]. - As of September 30, 2025, the number of shareholders for Junshi Bioscience was 35,900, an increase of 15.17% from the previous period [3]. Group 3: Market Performance - As of the latest report, Junshi Bioscience's stock price has decreased by 1.42%, with a trading volume of 173 million yuan and a turnover rate of 0.63%, bringing the total market capitalization to 36.478 billion yuan [3]. - The stock has experienced a 30% increase year-to-date, but has seen declines of 2.15% over the last five trading days, 3.50% over the last 20 days, and 22.15% over the last 60 days [3].